The assessment of glycosylated autoantigens as immunotolerance therapies is emerging as a potential strategy for the treatment of several autoimmune diseases, such as type 1 diabetes, Crohn’s disease ...
It was discovered that small positively charged peptide linkers could be attached to native, fully glycosylated antibodies at Q295 with excellent efficacy without the need for any antibody engineering ...
For mRNA decapping by enhancing DCP2's mRNA-binding affinity and regulating distinct biological processes through DCP1a and DCP1b, human DCP1 is essential.